beta-Nicotinamide mononucleotide

beta-Nicotinamide mononucleotide

Catalog Number:
FC01366265APE
Mfr. No.:
APE-B7878
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          beta-Nicotinamide mononucleotide (β-NMN) is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide[1].
          In a Nampt+/- mouse model of metabolic disease, β-NMN (50-100 µM) has been used to enhance NAD biosynthesis and glucose-stimulated insulin secretion, demonstrating a role for Nampt in β cell function[2].
          Furthermore, at 500 mg/kg/day, β-NMN has been shown to ameliorate glucose intolerance in high-fat diet-induced type 2 diabetes mice by restoring NAD+ levels[3].

          [1]. Gallí M, Van Gool F, Rongvaux A, et al. The nicotinamide phosphoribosyltransferase: A molecular link between metabolism, inflammation, and cancer. Cancer Research, 2010, 70: 8-11.
          [2]. Revollo J R, Körner A, Mills K F, et al. Nampt/PBEF/visfatin regulates insulin secretion in Β cells as a systemic NAD biosynthetic enzyme. Cell Metabolism, 2007, 6(5): 363-375.
          [3]. Yoshino J, Mills K F, Yoon M J, et al. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 2011, 14(4): 528-536.

      • Properties
        • Categories
          Intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+)
          Alternative Name
          ((2R,3S,4R,5R)-3,4-dihydroxy-5-(3-(hydroxy(imino)methyl)pyridin-1-ium-1-yl)tetrahydrofuran-2-yl)methyl hydrogen phosphate
          CAS Number
          1094-61-7
          Molecular Formula
          C11H16N2O8P
          Molecular Weight
          334.22
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          ≥33.4 mg/mL in H2O; insoluble in EtOH; insoluble in DMSO
          Storage
          Store at -20°C
          SMILES
          N=C(O)C1=C[N+]([[email protected]@]2([H])[[email protected]@](O)([H])[[email protected]@](O)([H])[[email protected]@](O2)([H])COP(O)([O-])=O)=CC=C1

          * For Research Use Only

      • Reference
        • 1. Peng, Tianqing. "Nicotinamide mononucleotide imparts protection against Doxorubicin-induced cardiotoxicity by maintaining lysosomal acidification." Western University, 8-4-2020.

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.